NASDAQ:CGEN Compugen - CGEN Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compugen Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. $0.70 -0.02 (-2.77%) (As of 03/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.70▼$0.7450-Day Range$0.68▼$0.9952-Week Range$0.51▼$3.57Volume80,683 shsAverage Volume225,552 shsMarket Capitalization$60.81 millionP/E RatioN/ADividend YieldN/APrice Target$4.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Compugen MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside783.2% Upside$6.20 Price TargetShort InterestHealthy2.44% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.41) to ($0.58) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.70 out of 5 starsMedical Sector828th out of 996 stocksBiological Products, Except Diagnostic Industry142nd out of 165 stocks 3.3 Analyst's Opinion Consensus RatingCompugen has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 5 buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.20, Compugen has a forecasted upside of 783.2% from its current price of $0.70.Amount of Analyst CoverageCompugen has only been the subject of 4 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.44% of the float of Compugen has been sold short.Short Interest Ratio / Days to CoverCompugen has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Compugen has recently decreased by 4.31%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCompugen does not currently pay a dividend.Dividend GrowthCompugen does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CGEN. Previous Next 1.0 News and Social Media Coverage News SentimentCompugen has a news sentiment score of -0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Medical companies.Search InterestOnly 13 people have searched for CGEN on MarketBeat in the last 30 days. This is a decrease of -28% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Compugen to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Compugen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.50% of the stock of Compugen is held by insiders.Percentage Held by InstitutionsOnly 25.34% of the stock of Compugen is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Compugen are expected to decrease in the coming year, from ($0.41) to ($0.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Compugen is -1.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Compugen is -1.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCompugen has a P/B Ratio of 0.78. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Compugen (NASDAQ:CGEN) StockCompugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses on research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.Read More Receive CGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Compugen and its competitors with MarketBeat's FREE daily newsletter. Email Address CGEN Stock News HeadlinesMarch 25, 2023 | americanbankingnews.comReviewing Prime Medicine (NYSE:PRME) & Compugen (NASDAQ:CGEN)March 15, 2023 | finance.yahoo.comCompugen to Present New Research Enabling Accurate Detection and Study of Novel Target PVRIG at AACR 2023April 2, 2023 | Vantage Point (Ad)Where Are The Markets Going Next?More banking collapses could be imminent. If you have any money (at all) invested in the markets... even just your retirement... you'll want to see THIS. What we reveal now could help you sooner (and you won’t want it to be later). March 14, 2023 | finance.yahoo.comIs Certara (CERT) Outperforming Other Medical Stocks This Year?March 13, 2023 | finance.yahoo.comCompugen (NASDAQ:CGEN investor three-year losses grow to 90% as the stock sheds US$11m this past weekMarch 10, 2023 | finance.yahoo.comCompugen Ltd. (NASDAQ:CGEN) Q4 2022 Earnings Call TranscriptMarch 8, 2023 | finance.yahoo.comCompugen to Participate in a Fireside Chat at the Oppenheimer 33rd Annual Healthcare ConferenceMarch 6, 2023 | finance.yahoo.comCompugen Doses First Patient in Triple Combination COM701, COM902 and Pembrolizumab MSS CRC Proof-of-Concept StudyApril 2, 2023 | Investorplace Media (Ad)5 Hypergrowth Stocks to Buy NowLuke Lango has found 14 stocks that have gone up over 1,000%. Now he’s named his top stocks for 2023. Just click to claim your copy. February 28, 2023 | finance.yahoo.comWhy Compugen Shares Are Up TodayFebruary 27, 2023 | finance.yahoo.comCompugen Reports Fourth Quarter and Full Year 2022 ResultsFebruary 13, 2023 | finance.yahoo.comCompugen to Release Fourth Quarter and Full Year 2022 Results on Monday, February 27, 2023February 9, 2023 | finance.yahoo.comCompugen to Present at the SVB Securities Global Biopharma ConferenceJanuary 23, 2023 | finance.yahoo.comCompugen to Participate in the JMP Securities C-Suite Series- TIGIT Landscape OverviewJanuary 6, 2023 | finance.yahoo.comWhy Shares of Compugen Rose on ThursdayDecember 14, 2022 | finance.yahoo.comCompugen's COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Durable Anti-Tumor Activity and Immune Activation in Patients with Platinum Resistant Ovarian CancerDecember 1, 2022 | finance.yahoo.comCompugen's COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Anti-Tumor Activity and Immune Activation in Platinum Resistant Ovarian Cancer PatientsNovember 30, 2022 | finance.yahoo.comWhy Shares of Compugen Rose 16.5% on WednesdayNovember 19, 2022 | msn.comWhy Shares of Compugen Jumped 17.86% on ThursdayNovember 16, 2022 | finance.yahoo.comCompugen to Receive Milestone Payment Triggered by AstraZeneca's Phase 2 Initiation of PD-1/TIGIT BispecificNovember 15, 2022 | finance.yahoo.comWhy Compugen Stock Crumbled TodayNovember 14, 2022 | finance.yahoo.comCompugen Reports Third Quarter 2022 ResultsNovember 11, 2022 | markets.businessinsider.comSVB Securities Sticks to Its Buy Rating for Compugen (CGEN)November 8, 2022 | finance.yahoo.comCompugen to Participate in the Stifel Healthcare ConferenceNovember 7, 2022 | finance.yahoo.comCompugen's COM701 (anti-PVRIG) Induces Potent Immune Activation in MSS-CRC PatientsNovember 7, 2022 | finance.yahoo.comCompugen's COM701 (anti-PVRIG) in Combination with Nivolumab Demonstrates Preliminary Anti-Tumor Activity and Potent Immune Activation in Metastatic MSS-CRC PatientsNovember 2, 2022 | finance.yahoo.comCompugen Announces Receipt of Nasdaq Delisting NoticeSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Compugen and its competitors with MarketBeat's FREE daily newsletter. Email Address CGEN Company Calendar Last Earnings2/27/2023Today4/01/2023Next Earnings (Estimated)5/15/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CGEN CUSIPN/A CIK1119774 Webwww.cgen.com Phone(723) 765-8585Fax972-3765-8555Employees73Year Founded1993Price Target and Rating Average Stock Price Forecast$6.20 High Stock Price Forecast$13.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+541.0%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-33,690,000.00 Net MarginsN/A Pretax Margin-448.48% Return on Equity-38.95% Return on Assets-31.73% Debt Debt-to-Equity RatioN/A Current Ratio7.23 Quick Ratio7.23 Sales & Book Value Annual Sales$7.50 million Price / Sales8.11 Cash FlowN/A Price / Cash FlowN/A Book Value$0.90 per share Price / Book0.78Miscellaneous Outstanding Shares86,630,000Free Float78,396,000Market Cap$60.81 million OptionableOptionable Beta2.70 Social Links Key ExecutivesAnat Cohen-DayagPresident, Chief Executive Officer & DirectorAlberto SessaChief Financial OfficerZurit LevineVice President-Technology InnovationEran OphirVice President-Research & Drug DiscoveryHenry AdewoyeChief Medical Officer & Senior Vice PresidentKey CompetitorsTScan TherapeuticsNASDAQ:TCRXCognition TherapeuticsNASDAQ:CGTXAptose BiosciencesNASDAQ:APTOX4 PharmaceuticalsNASDAQ:XFORGamida CellNASDAQ:GMDAView All CompetitorsInstitutional OwnershipMacquarie Group Ltd.Bought 162,941 shares on 2/21/2023Ownership: 0.985%Morgan StanleySold 329,663 shares on 2/15/2023Ownership: 0.855%Silverarc Capital Management LLCBought 667,443 shares on 2/15/2023Ownership: 0.770%Jane Street Group LLCBought 20,727 shares on 2/15/2023Ownership: 0.150%Mariner LLCBought 24,844 shares on 2/15/2023Ownership: 0.043%View All Institutional Transactions CGEN Stock - Frequently Asked Questions Should I buy or sell Compugen stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Compugen in the last twelve months. There are currently 1 sell rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CGEN shares. View CGEN analyst ratings or view top-rated stocks. What is Compugen's stock price forecast for 2023? 6 Wall Street research analysts have issued 12-month price targets for Compugen's shares. Their CGEN share price forecasts range from $2.00 to $13.00. On average, they expect the company's share price to reach $6.20 in the next twelve months. This suggests a possible upside of 783.2% from the stock's current price. View analysts price targets for CGEN or view top-rated stocks among Wall Street analysts. How have CGEN shares performed in 2023? Compugen's stock was trading at $0.7157 at the beginning of the year. Since then, CGEN stock has decreased by 1.9% and is now trading at $0.7020. View the best growth stocks for 2023 here. When is Compugen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 15th 2023. View our CGEN earnings forecast. How were Compugen's earnings last quarter? Compugen Ltd. (NASDAQ:CGEN) issued its earnings results on Monday, February, 27th. The biotechnology company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.10. The biotechnology company had revenue of $7.50 million for the quarter. During the same period in the prior year, the company earned ($0.10) EPS. What is Anat Cohen-Dayag's approval rating as Compugen's CEO? 2 employees have rated Compugen Chief Executive Officer Anat Cohen-Dayag on Glassdoor.com. Anat Cohen-Dayag has an approval rating of 100% among the company's employees. This puts Anat Cohen-Dayag in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Compugen own? Based on aggregate information from My MarketBeat watchlists, some companies that other Compugen investors own include Oramed Pharmaceuticals (ORMP), TransEnterix (TRXC), NVIDIA (NVDA), Advanced Micro Devices (AMD), QUALCOMM (QCOM), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Netflix (NFLX), Gilead Sciences (GILD) and Pfizer (PFE). What is Compugen's stock symbol? Compugen trades on the NASDAQ under the ticker symbol "CGEN." How do I buy shares of Compugen? Shares of CGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Compugen's stock price today? One share of CGEN stock can currently be purchased for approximately $0.70. How much money does Compugen make? Compugen (NASDAQ:CGEN) has a market capitalization of $60.81 million and generates $7.50 million in revenue each year. The biotechnology company earns $-33,690,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis. How can I contact Compugen? Compugen's mailing address is Azrieli Center 26 Harokmim Street Building D, Holon L3, 5885849. The official website for the company is www.cgen.com. The biotechnology company can be reached via phone at (723) 765-8585, via email at ir@cgen.com, or via fax at 972-3765-8555. This page (NASDAQ:CGEN) was last updated on 4/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.